Does Medicare Cover Red Light Therapy?

Medicare does not cover red light therapy, also called photobiomodulation or low-level light therapy, for the vast majority of conditions people seek it for. Traditional Medicare (Parts A and B) considers red light therapy experimental or investigational for most uses, which means there is no billing code that providers can use to get it reimbursed. This puts red light therapy in the same category as many other nonpharmacologic treatments that have growing research support but haven’t cleared the specific evidentiary and regulatory hurdles Medicare requires before it agrees to pay. That said, the picture is not entirely black and white, and a few narrow scenarios and plan types can change the answer.

Why Medicare Treats Red Light Therapy as Experimental

Medicare has a specific process for deciding what it will pay for. A treatment generally needs to be FDA-cleared or approved for the condition in question, supported by peer-reviewed evidence that meets Medicare’s standards, and recognized through an established billing pathway. Red light therapy devices have received FDA clearance as wellness or pain-relief devices in some cases, but that is different from FDA approval for treating a named medical condition. The distinction matters because Medicare does not pay for general “wellness” treatments. It pays for medically necessary interventions tied to a diagnosis.

The broader pattern is instructive. Medicare has historically been slow to cover nonpharmacologic pain therapies even when evidence supports them. A scoping review examining Medicare’s handling of such treatments noted that under traditional Medicare, coverage of nonpharmacologic approaches varies significantly depending on the type of pain and the specific therapy. Physical therapy is the most commonly covered outpatient service, while treatments like chiropractic care, acupuncture, and electrical nerve stimulation are only partially covered, often restricted by pain location, visit caps, or cost limits.¹ Red light therapy sits below even those partially covered treatments on Medicare’s priority list, because it lacks the condition-specific approvals and coding infrastructure those therapies have gradually built up.

What Red Light Therapy Is and How It Works

Red light therapy uses specific wavelengths of red and near-infrared light, typically between about 600 and 1,000 nanometers, delivered to the skin or body tissues. The light is absorbed by a protein in your cells’ mitochondria called cytochrome c oxidase, which plays a key role in cellular energy production. When this protein absorbs the light, it speeds up the electron transport chain, which increases oxygen consumption in the tissue and boosts the production of ATP, the molecule your cells use as fuel. This also increases local blood flow as the body sends more oxygenated blood to the treated area to meet the higher oxygen demand.²

The result, at least in theory and in a growing body of research, is reduced inflammation, faster tissue repair, and less pain. Practitioners use it for everything from joint pain and wound healing to skin rejuvenation and neurological conditions. The challenge for Medicare coverage is not that the mechanism is implausible but that the clinical evidence varies enormously by condition, and the treatment parameters (wavelength, dose, duration, frequency) are not standardized across studies, making it difficult for regulators to say definitively what works and for whom.

The Clinical Evidence That Does Exist

Research on red light therapy has been accumulating for decades, and several systematic reviews now paint a cautiously positive picture for certain conditions. For chronic pain, a systematic review of randomized clinical trials found that most included trials demonstrated significant pain reduction with photobiomodulation, particularly for fibromyalgia and neuropathy. Some studies also showed functional gains and improved quality of life, with a low incidence of adverse events.³ However, that same review noted that the wide variation in treatment parameters across studies makes it hard to standardize recommendations.

For knee osteoarthritis, a meta-analysis published in Physical Therapy found that photobiomodulation significantly reduced resting pain compared to placebo, though the certainty of evidence was rated very low. The treatment did not show a significant effect on functional mobility as measured by a timed walking test.⁴ “Very low certainty” is a technical rating that essentially means the true effect could be substantially different from what the studies found. It does not mean the treatment doesn’t work, but it does mean Medicare would be unlikely to view that evidence as meeting its threshold for coverage.

This pattern repeats across most conditions where red light therapy shows promise: the direction of the evidence is positive, but the quality and consistency are not yet strong enough for a large federal insurer to commit to paying for it. That gap between “probably helpful” and “proven effective in standardized protocols” is where red light therapy currently lives for most applications.

Oral Mucositis in Cancer Treatment Is the Strongest Case

If there is one area where red light therapy has come closest to the kind of clinical acceptance that could eventually influence coverage decisions, it is in preventing and treating oral mucositis, the painful mouth sores that develop in many cancer patients undergoing chemotherapy or radiation to the head and neck. Clinical practice guidelines now recommend photobiomodulation for preventing oral mucositis and related pain in patients receiving hematopoietic stem cell transplants, head and neck radiotherapy alone, and head and neck radiotherapy combined with chemotherapy.⁵

A separate systematic review confirmed that when photobiomodulation was used preventively, it reduced both the incidence of severe oral mucositis and the overall severity during the course of chemoradiotherapy. When used as a treatment after mucositis had already developed, it shortened the duration of the condition compared to placebo.⁶

This is meaningful because the evidence here is not just directionally positive with caveats. Formal clinical guidelines have been issued, and the condition is serious enough that cancer treatment centers increasingly offer it as part of supportive care. Some hospitals and cancer centers that provide photobiomodulation for oral mucositis may be able to bill it under broader supportive care or nursing service codes rather than as a standalone “red light therapy” procedure. Whether Medicare actually reimburses in those cases depends on how the facility codes the service, the Medicare Administrative Contractor that handles claims in that region, and whether the specific local coverage determination recognizes the treatment. In practice, coverage remains inconsistent even in this strongest use case.

Medicare Advantage Plans May Differ

Everything above applies to Original Medicare (Part A hospital insurance and Part B outpatient coverage). Medicare Advantage plans, the privately run alternatives offered under Part C, are required to cover everything Original Medicare covers, but they can add supplemental benefits beyond that baseline. Some Medicare Advantage plans have expanded their coverage of nonpharmacologic pain treatments, alternative therapies, or wellness benefits in recent years as part of their competitive positioning. A small number of these plans could theoretically include red light therapy under a supplemental benefit category, particularly for pain management.

This is not common, and you should not assume any given Medicare Advantage plan covers red light therapy without checking the specific plan’s evidence of coverage document. But it does mean that the answer to “does Medicare cover this” is not identical for every Medicare beneficiary. If you are enrolled in a Medicare Advantage plan and are interested in red light therapy, calling the plan directly and asking about photobiomodulation or low-level light therapy for your specific condition is the most reliable way to find out.

Paying Out of Pocket and Home Devices

Given the coverage gap, many people interested in red light therapy end up paying out of pocket. Professional treatments at clinics, physical therapy offices, or dermatology practices typically range from about $50 to $200 per session, with most providers recommending courses of multiple sessions over several weeks. The cost adds up quickly, which is part of why the coverage question matters so much to people on fixed incomes who make up a large share of Medicare beneficiaries.

Home-use red light therapy devices have become increasingly popular as a workaround. Panels, wraps, handheld wands, and even full-body beds are available for purchase, ranging from under $100 for small targeted devices to several thousand dollars for full-body panels. The FDA clears many of these as general wellness devices or for temporary relief of minor pain and stiffness, which is a much lower regulatory bar than approval for treating a specific medical condition. That lower bar means the devices can be sold legally, but it also means the manufacturer cannot claim the device treats or cures any disease.

The quality and power output of home devices vary wildly. A cheap handheld device may not deliver enough energy density to the target tissue to produce the effects seen in clinical research, where treatments use calibrated medical-grade equipment. If you are considering a home device, looking for one that specifies its wavelength (typically 630-670 nm for red and 810-850 nm for near-infrared), its power density in milliwatts per square centimeter, and its recommended treatment distance and duration will help you compare it to what has been used in studies. None of this changes the Medicare picture, but it is the practical reality facing most people who want to try the therapy.

Will Coverage Change in the Future?

The trajectory of evidence for photobiomodulation suggests that coverage decisions could shift in the coming years, though predicting when is difficult. Medicare’s history with nonpharmacologic therapies offers a useful parallel. Acupuncture, for example, had decades of growing evidence before Medicare finally began covering it for chronic low back pain in 2020, and even that coverage is limited to a specific number of sessions for a single condition.¹ If red light therapy follows a similar path, the likeliest entry point for Medicare coverage would be a single well-defined condition with strong enough evidence and clinical guidelines to justify a coverage determination.

Oral mucositis remains the leading candidate for that kind of breakthrough, given that formal clinical practice guidelines already exist. Pain conditions like fibromyalgia and peripheral neuropathy are further behind but accumulating evidence. The chronic pain space is where Medicare has shown the most willingness to expand nonpharmacologic coverage, partly driven by the push to reduce opioid prescribing.

Newer research areas could also play a role. A study of photobiomodulation for dry age-related macular degeneration, a condition that affects millions of older adults, found that treated patients were more than twice as likely to gain five or more letters of visual acuity compared to a sham group over four months. The treated group also showed a significant reduction in drusen volume, the deposits under the retina that characterize the disease.⁷ Dry macular degeneration currently has limited treatment options, and if larger trials confirm these early findings, it could create another avenue for coverage consideration since the affected population is overwhelmingly Medicare-age.

What to Do if You’re on Medicare and Want Red Light Therapy

Your first step should be confirming what type of Medicare coverage you have. If you are on Original Medicare, red light therapy will almost certainly not be covered for any condition at present. If you are on a Medicare Advantage plan, it is worth checking your plan’s supplemental benefits or calling member services to ask specifically about photobiomodulation or low-level light therapy.

If you are receiving cancer treatment and your oncology team recommends photobiomodulation for oral mucositis prevention, ask the treatment center how they bill it. Some centers absorb the cost into broader supportive care, while others may bill it separately. The billing approach can determine whether Medicare’s claims processing system flags it for denial or lets it through as part of a covered service bundle.

For pain conditions, you might explore whether your provider can offer red light therapy as part of a physical therapy or rehabilitation session that is itself covered by Medicare Part B. The therapy session as a whole may be covered even if one specific modality used during the session (like a light therapy device) would not be covered on its own. This is a gray area that depends on how the provider documents and codes the visit, and not all providers will be willing to navigate it.

Finally, if you are considering purchasing a home device, understand that Medicare will not reimburse you for it. Home red light therapy devices are classified as consumer wellness products, not durable medical equipment, and there is no Medicare benefit category they fit into. The entire cost will come out of your pocket. Some Health Savings Accounts or Flexible Spending Accounts may cover these devices, but those are not Medicare programs.

Red Light Therapy vs. Photodynamic Therapy

One source of confusion worth clearing up is the difference between red light therapy and photodynamic therapy, because the two sound similar but are treated very differently by Medicare. Photodynamic therapy uses a photosensitizing drug applied to the skin or administered intravenously, followed by exposure to a specific wavelength of light that activates the drug to destroy targeted cells. It is FDA-approved for certain skin cancers, precancerous skin lesions, and some other conditions, and Medicare does cover it for those approved uses.

Red light therapy, by contrast, uses light alone without any photosensitizing agent. The mechanism is entirely different: instead of destroying cells with a drug-light combination, it aims to stimulate cellular energy production and healing. Because they are fundamentally different treatments with different regulatory statuses, Medicare’s coverage of photodynamic therapy tells you nothing about its position on red light therapy. If a provider suggests that Medicare will cover your “light therapy,” make sure you understand which treatment they mean and what specific billing codes they plan to use.